Lumbrokinase

CAS NO.: 556743-18-1
Source: Earthworm
Appearance:Off White powder
Test Method:HPLC
Product Specification: 99%
Description About Lumbrokinase CAS 556743-18-1
Lumbrokinase is an enzyme derived from Lumbricus rubellus, a species of earthworm. Sold as a dietary supplement, lumbrokinase is classified as a fibrinolytic enzyme (a substance that promotes the breakdown of fibrinogen, a protein involved in blood clotting). Supplementing with lumbrokinase is thought to offer health benefits, including the prevention of stroke and the treatment of angina (coronary chest pains).
Lumbrokinase is a new enzyme supplement known to benefit the circulation and characteristics of the blood. It is a promising new tool for those seeking to protect from heart disease. it contains the enzyme lumbrokinase, which has been shown to assist with the breakdown of fibrin, a protein involved in blood clotting. It has proven valuable in acute, subacute, and chronic conditions associated with clotting tendencies and poor circulation.Supplementing with lum helps to maintain an optimal environment for healthy circulation. It is also recommended for people using this supplementation . Long term toxicological tests in experimental animals showed that lumbrokinase is non toxic, free of side effects on the functioning of the heart, liver, kidney, respiratory and nervous systems.
Lumbrokinase is being investigated as an antithrombotic agent. Thrombocytes, also known as platelets, are red blood cells that clump together whenever tissues are compromised to help stop bleeding.
Antithrombotic agents work by inhibiting the blood cells' ability to stick together. This can be valuable in preventing or lessening the impact of diseases like stroke, myocardial infarction (heart attack), and deep vein thrombosis (DVT).
Lumbrokinase may aid in the treatment of stable angina, says a 2009 study in the Journal of Alternative and Complementary Medicine. For this study, researchers assigned 10 people with angina a daily dose of lumbrokinase in addition to standard cardiovascular care. After 60 days, angina symptoms had improved in all but four patients.